Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 144

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 144
---
 Stock. Specifically, its two co-founders, Kira Sheinerman and Samuil Umansky, who are daughter and father,
own and control a combined 84.9% of DiamiR’s currently outstanding common stock, with Dr. Sheinerman, who is also its
Executive Director, owning approximately 44.9% of outstanding common stock, and Dr. Umansky, who has retired as its Chief Scientific
Officer, owning approximately 40.0% of outstanding common stock. Furthermore, DiamiR’s Bylaws provide that “any action
which may be taken by the vote of the stockholders at an annual or special meeting may be taken without a meeting if authorized by
the written consent of stockholders holding at least a majority of the voting power.” Accordingly, and as a result of their
ownership, these two shareholders of DiamiR currently control substantially all matters requiring approval by DiamiR’s
stockholders, including the election of all directors and approval of significant corporate transactions. This could make it
impossible for other stockholders to influence the affairs of DiamiR and could delay or prevent an outside party from acquiring or
merging with DiamiR even if its other shareholders wanted it to occur. This concentration of ownership may also have the effect of
delaying or preventing a change of control of DiamiR or discouraging others from making tender offers for its shares, which could
prevent its stockholders from receiving a premium for its shares. Some of these persons or entities who make up DiamiR’s
principal stockholders may have interests different from other shareholders of DiamiR.

Risks Related to DiamiR’s Products and Service

If researchers, clinicians and healthcare administrators do not adopt DiamiR’s screening and diagnostic products, it will not achieve future sales growth.

DiamiR’s business model
is heavily reliant on the adoption of its products by researchers, clinicians, and healthcare administrators (“Industry Advocates”).
These professionals play a critical role in the healthcare ecosystem, influencing both the acceptance and the utilization of new medical
technologies. A failure to secure and maintain adoption among these groups poses a significant risk to DiamiR’s operations. New
products frequently are subject of slow adoption by healthcare specialists partly due to perceived liability risks and the uncertainty
of third-party reimbursement. It is critical to the success of DiamiR’s future sales growth that it continues to work with key opinions
leaders in the field, educate healthcare specialists about Cogni